Protalix BioTherapeutics (PLX) Other Operating Expenses (2011 - 2026)

Protalix BioTherapeutics has reported Other Operating Expenses for 12 years, with the latest figure at -$7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Other Operating Expenses fell 1778.33% year-over-year to -$7.6 million; the trailing twelve-month figure through Mar 2026 stood at -$18.8 million (down 408.96% YoY), and the FY2025 full-year result was -$11.7 million, down 34.19% from the prior year.
• Other Operating Expenses for Q1 2026 stood at -$7.6 million, down from -$6.9 million in the prior quarter.
• The five-year high for Other Operating Expenses was $1.4 million in Q3 2024, with the low at -$7.6 million in Q1 2026.
• Average Other Operating Expenses over 3 years is -$2.8 million, with a median of -$2.3 million recorded in 2025.
• Year-over-year, Other Operating Expenses declined 24.45% in 2025 and tumbled 1778.33% in 2026.
• Tracing PLX's Other Operating Expenses over 3 years: stood at -$5.6 million in 2024, then decreased by 24.45% to -$6.9 million in 2025, then fell by 10.23% to -$7.6 million in 2026.
• The last three Other Operating Expenses figures came in at -$7.6 million (Q1 2026), -$6.9 million (Q4 2025), and $22000.0 (Q3 2025), per Business Quant data.

Peer Comparison